🏃‍♂️Enjoyed the day at ProMedica Stroke Network’s BE FAST 5K Run for Stroke with my phenomenal colleague and friend, Michael D. Hill. Excited to be a part of Basking Biosciences on our mission to revolutionize thrombolytics.💜

🚀 What an incredible kickoff in Sydney! Our Basking Biosciences team just wrapped up a high-energy, focused investigator meeting to prepare for the upcoming BB-031 RAISE Trial Part B. Thank you to everyone who participated in person and virtually! #vWF #Phase2B

ICYMI: We presented exciting updates on BB-031 at #ESOC2025, highlighting the RAISE trial—a Phase 2 patient study evaluating BB-031, a novel RNA aptamer that targets von Willebrand Factor (vWF) for the treatment of acute ischemic stroke. Learn more: 🔗

Great to see the Basking team in action at #ESOC2025. Energizing to connect with our global investigators and longtime advisors—all pushing stroke research forward. Big thanks to all who joined us in Helsinki! 👋 #StrokeResearch #ClinicalTrials #GlobalCollaboration

🧠⚡Stroke is treatable—and we’re developing the next chapter in care. Learn how BB-031 could shift the paradigm of ischemic stroke treatment: https://t.co/jwaBekYFrQ   #AHAstrokemonth

Thanks to the Solas BioVentures team for the invite! Grateful for the chance to connect and have great conversations around even greater science! @AdairDaveadair @SolasBio

🧠⚡Stroke is a leading cause of death and disability—but early action saves lives. This #StrokeAwarenessMonth, know the signs (FAST) and share them. Let’s be faster than stroke. 🔗

Just returned from the International Stroke Conference with another jolt of data about who to treat for #stroke! Always great to see and spend time with friends!! @StavTjoumakaris @shazamhussain @TudorGJovin @AmeerEHassan @BrettWa11 @Fie0815 @NimaE @ShahidNimjee

Great discussion with @CMichaelGibson about von Willebrand Factor’s role in blood clot formation and contraction and its potential as a target for ischemic stroke treatment. Excited to be advancing our novel thrombolytic BB-031 through Ph 2 in the clinic! 

Incredible start to 2025! Thrilled to join such a talented, passionate team for brainstorming, planning, and celebrating our shared mission. Here’s to a transformative year ahead!

Newly published research reports the superior efficacy and safety of novel RNA aptamer BB-031, compared to the standard treatment with rTPA in a canine model of basilar artery occlusion. https://t.co/9ZtBwJ29Eq. @NeurosurgeryOSU @OSUNeuroscience

⏰ Stroke can’t wait. Neither should we. I’m proud to be working with our Basking Biosciences team to develop innovative treatments that extend the critical time window and expand access for stroke patients. #WorldStrokeDay2024

Honored to have Dr. Adnan Qureshi and Dr Shahid Nimjee join us in Toledo for the Annual Stroke Update Conference … we had an excellent turnout and amazing talks … good times and memories! @Mouhammad_Jumaa @ShahidNimjee

🤔 How much do you know about #thrombosis? On #WorldThrombosisDay, learn about blood clots (thrombus) within blood vessels that obstruct blood flow and lead to acute ischemic stroke, as well as Basking's approach to address #AIS.

Thank you to @ShahidNimjee, one of our dual trained open/endovascular experts, for the great Grand Rounds talk on mechanical thrombectomy for LVO stroke! 🧠

Rerupture of an Aneurysmal Subarachnoid Hemorrhage | New England Journal of Medicine https://t.co/2IrKpZ2eqE

Patient dosing has commenced for the phase 2 RAISE study, a pivotal, 2-part trial assessing the safety and preliminary efficacy of BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor in patients with #AIS. @ShahidNimjee @OSUWexMed https://t.co/t8qgHRgN4G

Next generation pharmaceutical technologies @deepwelldtx will be led by @RussellLonser:

Here is @ShahidNimjee, one of OSU’s dual trained vascular experts, giving a talk at the OHSNS annual meeting on the endovascular treatment of aneurysms.

Phase 2 trial underway to test vWF inhibition in AIS patients. @NeurosurgeryOSU